For advanced ESCC patients with PD-L1 combination positive score (CPS) ≥10, the benefit was even greater in the serplulimab plus chemotherapy group compared with chemotherapy alone group (median PFS, 7.1 vs. 5.3 months; HR = 0.60; p< 0.0001; median OS, 18.6 vs.13.9 months; HR = 0.59; p = 0.0082). Here, CD274 is linked to esophageal squamous cell carcinoma.